JP5918235B2 - フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法 - Google Patents

フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法 Download PDF

Info

Publication number
JP5918235B2
JP5918235B2 JP2013523380A JP2013523380A JP5918235B2 JP 5918235 B2 JP5918235 B2 JP 5918235B2 JP 2013523380 A JP2013523380 A JP 2013523380A JP 2013523380 A JP2013523380 A JP 2013523380A JP 5918235 B2 JP5918235 B2 JP 5918235B2
Authority
JP
Japan
Prior art keywords
fucose
aryl
alkyl
fucosylation
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013523380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013541503A (ja
JP2013541503A5 (enExample
Inventor
センター，ピーター
アレー，スティーブン
ベンジャミン，デニス
Original Assignee
シアトル ジェネティクス，インコーポレーテッド
シアトル ジェネティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアトル ジェネティクス，インコーポレーテッド, シアトル ジェネティクス，インコーポレーテッド filed Critical シアトル ジェネティクス，インコーポレーテッド
Publication of JP2013541503A publication Critical patent/JP2013541503A/ja
Publication of JP2013541503A5 publication Critical patent/JP2013541503A5/ja
Application granted granted Critical
Publication of JP5918235B2 publication Critical patent/JP5918235B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2013523380A 2010-08-05 2011-08-05 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法 Expired - Fee Related JP5918235B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37111610P 2010-08-05 2010-08-05
US61/371,116 2010-08-05
PCT/US2011/046857 WO2012019165A2 (en) 2010-08-05 2011-08-05 Methods of inhibition of protein fucosylation in vivo using fucose analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016076930A Division JP6113887B2 (ja) 2010-08-05 2016-04-07 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法

Publications (3)

Publication Number Publication Date
JP2013541503A JP2013541503A (ja) 2013-11-14
JP2013541503A5 JP2013541503A5 (enExample) 2014-09-25
JP5918235B2 true JP5918235B2 (ja) 2016-05-18

Family

ID=45560106

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013523380A Expired - Fee Related JP5918235B2 (ja) 2010-08-05 2011-08-05 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法
JP2016076930A Expired - Fee Related JP6113887B2 (ja) 2010-08-05 2016-04-07 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法
JP2017049534A Expired - Fee Related JP6622238B2 (ja) 2010-08-05 2017-03-15 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法
JP2019210313A Pending JP2020040974A (ja) 2010-08-05 2019-11-21 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016076930A Expired - Fee Related JP6113887B2 (ja) 2010-08-05 2016-04-07 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法
JP2017049534A Expired - Fee Related JP6622238B2 (ja) 2010-08-05 2017-03-15 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法
JP2019210313A Pending JP2020040974A (ja) 2010-08-05 2019-11-21 フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法

Country Status (21)

Country Link
US (4) US9504702B2 (enExample)
EP (2) EP3513794A3 (enExample)
JP (4) JP5918235B2 (enExample)
KR (2) KR20190022884A (enExample)
CN (2) CN107007615A (enExample)
AU (3) AU2011285490B2 (enExample)
CA (1) CA2803388C (enExample)
CY (1) CY1121419T1 (enExample)
DK (1) DK2608796T3 (enExample)
ES (1) ES2711622T3 (enExample)
HU (1) HUE043370T2 (enExample)
IL (2) IL224487A (enExample)
MX (1) MX356671B (enExample)
NZ (1) NZ606250A (enExample)
PL (1) PL2608796T3 (enExample)
PT (1) PT2608796T (enExample)
RU (2) RU2625768C2 (enExample)
SI (1) SI2608796T1 (enExample)
TR (1) TR201902439T4 (enExample)
WO (1) WO2012019165A2 (enExample)
ZA (1) ZA201300653B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210135218A (ko) 2018-12-27 2021-11-12 각고호우징 게이오기주크 항인간 노로바이러스제

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
EP3513794A3 (en) 2010-08-05 2019-10-16 Seattle Genetics, Inc. Fucose analogs for inhibition of protein fucosylation in vivo
EP2887947B1 (en) * 2012-08-23 2019-06-05 Seattle Genetics, Inc. Fucose analogues for the treatment of sickle cell disease
EP2958905B1 (en) 2013-02-22 2017-03-29 Amgen Inc. Carbohydrate phosphonate derivatives as modulators of glycosylation
CN106699886A (zh) * 2015-07-13 2017-05-24 西藏海思科药业集团股份有限公司 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体
SG11201804263PA (en) * 2015-12-04 2018-06-28 Seattle Genetics Inc Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
WO2017194605A1 (en) * 2016-05-10 2017-11-16 Ares Trading S.A. Methods for modulating protein galactosylation profiles of recombinant proteins using peracetyl galactose
JP2018002666A (ja) * 2016-07-04 2018-01-11 国立研究開発法人理化学研究所 フコース類似体と糖を検出する方法
MA50865A (fr) * 2017-06-07 2020-04-15 Seattle Genetics Inc Lymphocytes t à fucosylation de surface réduite et procédés de production et d'utilisation de ceux-ci
CN111615520A (zh) 2017-12-01 2020-09-01 辉瑞大药厂 抗cxcr5抗体及其组合物和用途
WO2019190984A1 (en) 2018-03-29 2019-10-03 Pfizer Inc. Lfa3 variants and compositions and uses thereof
EP3841123A2 (en) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit antibodies
US20230022796A1 (en) * 2019-12-19 2023-01-26 Merck Patent Gmbh Methods and compositions for modulating the glycosylation profile of proteins
TWI877278B (zh) * 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
US20230331649A1 (en) * 2020-06-03 2023-10-19 Simon Fraser University Inhibitors of protein fucosylation and uses thereof
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2025262564A1 (en) 2024-06-17 2025-12-26 Pfizer Inc. Use of anti-cxcr5 antibodies
CN121588117A (zh) * 2025-12-29 2026-03-03 大连医科大学附属第一医院 2-氟岩藻糖在制备减轻急性肾损伤的药物中的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440780A (en) 1979-06-01 1984-04-03 Chevron Research Company Fungicidal 3-(N-acyl-N-arylamino)-and 3-(N-thionoacyl-N-arylamino)-gamma-butyrolactones and gamma-thiobutyrolactones
JPH0660189B2 (ja) 1986-01-22 1994-08-10 財団法人微生物化学研究会 ２，６−ジデオキシ−２−フルオロ−ｌ−タロピラノ−ス又はその誘導体とその製造法
FR2630914A1 (fr) 1988-05-04 1989-11-10 Hoechst Sa Laboratoires Nouveaux analogues du l-fucose, leur procede de preparation, application de ces analogues a la preparation de nouveaux glycals, anthracyclines obtenues a l'aide de ces glycals et utilisation desdites anthracyclines en tant que medicaments
KR100211417B1 (ko) 1990-11-30 1999-10-01 유충식 L-탈로피라노시드 유도체 및 그의 제조방법
US5461143A (en) 1991-03-18 1995-10-24 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US5210078A (en) * 1991-04-30 1993-05-11 The Biomembrane Institute Trifluoromethyl analogs of fucose and uses thereof
ATE174925T1 (de) 1991-10-15 1999-01-15 Scripps Research Inst Herstellung von fucosylierten kohlenhydraten durch enzymatische fucosylierungs-synthese der zuckernukleotide; und in situ regeneration von gdp-fucose
DE69425439D1 (de) 1993-09-29 2000-09-07 Nissin Food Products Ltd In stellung 21 substituierte steroide
US5481143A (en) 1993-11-15 1996-01-02 Burdick; Brian K. Self starting brushless d.c. motor
FR2723947B1 (fr) 1994-08-31 1996-09-27 Adir Nouveaux composes tetrahydropyraniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19524515A1 (de) 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US6713287B1 (en) 1995-10-24 2004-03-30 The Scripps Research Institute Enzymatic synthesis of L-fucose and L-fucose analogs
WO1998018805A2 (en) * 1996-10-28 1998-05-07 Novartis Ag Sugar derivatives as sialyl lewis x mimetics
US5770407A (en) 1996-12-10 1998-06-23 The Scripps Research Institute Process for preparing nucleotide inhibitors of glycosyltransferases
JP4451933B2 (ja) 1996-12-27 2010-04-14 住友化学株式会社 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法
US6075134A (en) 1997-05-15 2000-06-13 The Regents Of The University Of California Glycoconjugates and methods
JPH1135593A (ja) 1997-07-18 1999-02-09 Daikin Ind Ltd ２−フルオロフコシル−ｎ−アロイルグルコサミン誘導体及びその中間物、並びにそれらの製造方法
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
AU2004204778B2 (en) 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
US7332334B2 (en) 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
EP1642971B1 (en) 2003-06-18 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Fucose transporter
JPWO2005035741A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 ゲノムが改変された細胞
WO2005061523A1 (en) 2003-12-23 2005-07-07 Progen Industries Limited Glycosaminoglycan (gag) mimetics
DE102004032421A1 (de) 2004-07-05 2006-01-26 Bayer Cropscience Ag Phenylsubstituierte [1.2]-Oxazin-3,5-dion-und Dihydropyron-Derivate
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
US8067546B2 (en) 2005-04-19 2011-11-29 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
DK1945665T3 (da) 2005-10-21 2012-02-06 Genzyme Corp Antistof-baserede terapimidler med forhøjet ADCC-aktivitet
US8278349B2 (en) 2005-11-28 2012-10-02 Ramot At Tel-Aviv University Ltd. Cancer treatment using FTS and 2-deoxyglucose
WO2007071051A1 (en) * 2005-12-21 2007-06-28 Viventia Biotech Inc. Novel cancer-associated antigen
WO2007081031A1 (ja) 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
US20070249014A1 (en) 2006-02-10 2007-10-25 Invitrogen Corporation Labeling and detection of post translationally modified proteins
CN101426508A (zh) 2006-02-24 2009-05-06 得克萨斯系统大学评议会 治疗癌症的己糖化合物
EP1986660A4 (en) 2006-02-24 2009-08-26 Univ Texas HEXOSE COMPOUNDS FOR CANCER TREATMENT
WO2007111952A2 (en) 2006-03-22 2007-10-04 The Scripps Research Institute Method of preparing glycopeptides
US9149489B2 (en) 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2009108926A1 (en) 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
CA2663536A1 (en) 2006-10-24 2008-05-02 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
WO2008100453A1 (en) 2007-02-09 2008-08-21 Glycomimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer
CN101062939A (zh) 2007-05-17 2007-10-31 北京热景生物技术有限公司 检测肝癌岩藻糖基化高尔基蛋白gp73的装置及试剂盒
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
CA2717614A1 (en) 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced adcc function
PL2282773T3 (pl) * 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
WO2009143078A2 (en) 2008-05-19 2009-11-26 Board Of Regents, The University Of Texas System Methods of treating brain cancer using hexose compounds
US20110183926A1 (en) 2008-05-23 2011-07-28 University Of Miami Treatment using continuous low dose application of sugar analogs
JP2011524375A (ja) * 2008-06-16 2011-09-01 アカデミア シニカ ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用
US20120100609A1 (en) 2009-03-27 2012-04-26 Crawford Brett E N-linked glycan biosynthesis modulators
US20150259371A1 (en) * 2010-05-06 2015-09-17 Simon Fraser University Methods and compounds for inhibiting glycosyltransferases
US20110288880A1 (en) 2010-05-07 2011-11-24 Patient Care Automation Services, Inc. Targeted health care messaging
EP3513794A3 (en) 2010-08-05 2019-10-16 Seattle Genetics, Inc. Fucose analogs for inhibition of protein fucosylation in vivo
WO2012097052A2 (en) 2011-01-11 2012-07-19 Intertech Bio, Llc Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
US8979675B2 (en) 2012-04-25 2015-03-17 Nike, Inc. Golf ball core having radial appendages
EP2887947B1 (en) 2012-08-23 2019-06-05 Seattle Genetics, Inc. Fucose analogues for the treatment of sickle cell disease
SG11201804263PA (en) 2015-12-04 2018-06-28 Seattle Genetics Inc Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210135218A (ko) 2018-12-27 2021-11-12 각고호우징 게이오기주크 항인간 노로바이러스제

Also Published As

Publication number Publication date
US20210260086A1 (en) 2021-08-26
CN107007615A (zh) 2017-08-04
US9504702B2 (en) 2016-11-29
ZA201300653B (en) 2014-03-26
PT2608796T (pt) 2019-02-25
AU2011285490A1 (en) 2013-01-10
AU2017279653A1 (en) 2018-01-18
WO2012019165A2 (en) 2012-02-09
AU2011285490B2 (en) 2016-04-21
US10342811B2 (en) 2019-07-09
CA2803388C (en) 2019-11-05
RU2013109415A (ru) 2014-09-10
JP6113887B2 (ja) 2017-04-12
IL224487A (en) 2016-07-31
HUE043370T2 (hu) 2019-08-28
RU2017122482A3 (enExample) 2019-01-30
TR201902439T4 (tr) 2019-03-21
KR20190022884A (ko) 2019-03-06
RU2017122482A (ru) 2019-01-30
JP2017149723A (ja) 2017-08-31
PL2608796T3 (pl) 2019-04-30
KR20130135240A (ko) 2013-12-10
DK2608796T3 (en) 2019-03-18
EP2608796B1 (en) 2018-11-21
JP2016175909A (ja) 2016-10-06
MX356671B (es) 2018-06-08
CY1121419T1 (el) 2020-05-29
CA2803388A1 (en) 2012-02-09
US20170035790A1 (en) 2017-02-09
RU2625768C2 (ru) 2017-07-18
JP2013541503A (ja) 2013-11-14
EP3513794A2 (en) 2019-07-24
MX2013001303A (es) 2014-07-24
US20130129784A1 (en) 2013-05-23
US20200061091A1 (en) 2020-02-27
WO2012019165A3 (en) 2013-08-15
US11033561B2 (en) 2021-06-15
CN103402525A (zh) 2013-11-20
JP2020040974A (ja) 2020-03-19
NZ606250A (en) 2015-04-24
KR101950520B1 (ko) 2019-02-20
CN103402525B (zh) 2017-03-01
ES2711622T3 (es) 2019-05-06
EP3513794A3 (en) 2019-10-16
IL244019A0 (en) 2016-04-21
EP2608796A2 (en) 2013-07-03
AU2016204495A1 (en) 2016-07-21
JP6622238B2 (ja) 2019-12-18
SI2608796T1 (sl) 2019-03-29
IL244019B (en) 2019-09-26
EP2608796A4 (en) 2014-06-11

Similar Documents

Publication Publication Date Title
JP6622238B2 (ja) フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法
JP6774941B2 (ja) 免疫原性／治療用糖コンジュゲート組成物およびその使用
TW201521766A (zh) 碳水化合物疫苗之化合物及組成物以及其用途
EP4445919A1 (en) Antibody-drug conjugate having improved affinity, and preparation method therefor and application thereof
HK40011525A (en) Fucose analogs for inhibition of protein fucosylation in vivo
CN117651566A (zh) 用于癌的治疗和/或预防的药品
JP7023460B2 (ja) Ｔｌｒリガンド固定化ナノ粒子
HK1186659B (en) Inhibition of protein fucosylation in vivo using fucose analogs
HK1186659A (en) Inhibition of protein fucosylation in vivo using fucose analogs
US20230331649A1 (en) Inhibitors of protein fucosylation and uses thereof
HK40131427A (en) Inhibitors of protein fucosylation and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160407

R150 Certificate of patent or registration of utility model

Ref document number: 5918235

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees